Efficacy of Zengye Chengqi decoction combined with olanzapine in the treatment of schizophrenia of Yangming Fushi syndrome

Abstract

BackgroundPatients with schizophrenia of Yangming Fushi syndrome experience more severe symptoms， and a substantial proportion of patients derive inadequate benefit from antipsychotics and suffer from serious adverse effects， yet few studies have been conducted on the treatment of schizophrenia of Yangming Fushi syndrome with Zengye Chengqi decoction.ObjectiveTo explore the efficacy of Zengye Chengqi decoction combined with olanzapine in the treatment of schizophrenia of Yangming Fushi syndrome， in order to provide references for the treatment of schizophrenia with the combination of traditional Chinese and western medicine.MethodsA total of 60 patients attending the Second Affiliated Hospital of Xinxiang Medical College from January 2022 to August 2023 and fulfilling the International Classification of Diseases （ICD-10） diagnostic criteria for schizophrenia were enrolled， and assigned into study group （n=30） and control group （n=30） using random number table methods. All patients were treated with olanzapine， and study group was given Zengye Chengqi decoction on this basis. Treatment for both groups lasted for 4 weeks. All participants were assessed using Positive and Negative Syndrome Scale （PANSS）， Montreal Cognitive Assessment （MoCA） and Event-Related Potential P300 at baseline and end of treatment. The occurrence of adverse reactions was recorded at the end of treatment.ResultsStudy group reported a higher treatment effective rate compared with control group （χ2=9.320， P=0.002）. After treatment， study group detected a significant reduction in PANSS subscales and total scores （F=10.287， 8.258， 8.844， 20.079， P<0.01）， and a notable increase in scores of delayed recall and orientation domains from MoCA （F=4.463， 22.255， P<0.05 or 0.01） when compared with control group， with statistical difference. For the P3 component of event-related potential， study group produced significantly larger amplitudes than control group （F=4.247， P<0.05）. The incidence rate of abnormal liver function， constipation and increased body mass index （BMI） in study group was lower than those in control group （χ2=4.320， 4.463， 7.200， P<0.05 or 0.01）.ConclusionZengye Chengqi decoction combined with olanzapine are found to be effective in improving the psychotic symptoms and cognitive function and alleviating the adverse reactions of patients with schizophrenia of Yangming Fushi syndrome. ［Funded by Open Project of Psychiatry and Neuroscience Discipline of Second Affiliated Hospital of Xinxiang Medical College （number， XYEFYJSSJ-2023-09）； www.chictr.org.cn number： ChiCTR2200057743］

Keywords

• zengye chengqi decoction
• olanzapine
• schizophrenia
• yangming fushi syndrome
• event-related potential p300